Canmab 150mg Injection, Biocon

Name: Canmab 150mg Injection, Biocon
Brand: BALAJI CHEMICAL STORES
Price: 15000.0 INR
Availability: InStock

Price 15000.0 INR/ Piece

Get a Price/Quote

MOQ : 10 Pieces

Canmab 150mg Injection, Biocon Specification

Brand Name
Canmab

Life Span
Refer to expiry date on the package (typically 2 years from manufacture date)

Salt Composition
Trastuzumab 150 mg

Indication
HER2 positive breast cancer, Gastric cancer

Dosage Form
Lyophilized Powder for Injection

Origin of Medicine
India

Pacakaging (Quantity Per Box)
1 vial per box

Packaging Type
Vial, Box

Drug Type
Allopathic

Ingredients
Trastuzumab

Physical Form
Injection

Function
Monoclonal Antibody, Targeted Therapy for cancer

Recommended For
Breast Cancer, Metastatic Breast Cancer, HER2 positive patients

Dosage
As directed by physician

Dosage Guidelines
Follow the oncologists advice and administration schedule

Suitable For
Adults

Quantity
150 mg per vial

Storage Instructions
Store in a refrigerator at 2C to 8C. Do not freeze.

Precautions
To be administered under supervision of a qualified healthcare professional

Route of Administration
Intravenous (IV) infusion

Colour
White to off-white lyophilized cake

Therapeutic Class
Antineoplastic, Monoclonal Antibody

Prescription Required
Yes

Marketed By
Biocon Ltd

Regulatory Approval
DCGI Approved (India)

Patient Age Group
Adults

Reconstitution Required
Yes, with sterile water for injection

About Canmab 150mg Injection, Biocon

Trastuzumab injection is a targeted monoclonal antibody used to treat HER2-positive breast and gastric cancers. It binds to the HER2 receptor, inhibiting tumor growth and enhancing immune response. Often combined with chemotherapy, it significantly improves survival and disease-free outcomes in eligible patients.

Targeted Therapy for HER2 Positive Cancers

Canmab 150mg Injection is a specialized monoclonal antibody designed to target HER2 receptors found in certain breast and gastric cancers. By interfering with HER2 receptor pathways, it helps control cancer growth and progression, providing significant benefits for eligible patients. Its targeted approach often results in more precise management of specific cancer types.

Proper Administration and Handling

Reconstitution of Canmab requires sterile water for injection and should only be performed by trained healthcare professionals. The medicine is intended for intravenous infusion and requires careful adherence to dosing schedules set by your oncologist. Correct storage and handling, including refrigeration, are vital to maintaining efficacy and safety.

FAQ's of Canmab 150mg Injection, Biocon:

Q: How is Canmab 150mg Injection prepared and administered?

A: Canmab 150mg Injection comes as a lyophilized powder that must be reconstituted with sterile water for injection by a healthcare professional. After reconstitution, it is administered as an intravenous infusion under strict medical supervision.

Q: What conditions is Canmab 150mg Injection recommended for?

A: Canmab is specifically indicated for adults diagnosed with HER2 positive breast cancer, including metastatic cases, and certain HER2 positive gastric cancers, as part of targeted therapy regimens.

Q: When should I receive my Canmab 150mg Injection doses?

A: Your oncologist will set the dosing schedule for Canmab based on your individual treatment plan, cancer type, and response to therapy. Strict adherence to the prescribed schedule is crucial for optimal results.

Q: Where should Canmab 150mg Injection be stored before use?

A: Canmab should be stored in a refrigerator between 2C and 8C. Do not freeze the vial. Keep it in its original packaging until ready for reconstitution and use.

Q: What precautions should be taken during Canmab 150mg Injection administration?

A: Administration must be performed under the supervision of a qualified healthcare professional to manage any potential infusion reactions or side effects. It is not for self-administration.

Q: What benefits does Canmab 150mg Injection offer in cancer treatment?

A: Canmab provides targeted therapy against HER2 positive cancers, interfering with cancer cell growth and proliferation, which may lead to improved clinical outcomes and disease management for eligible patients.

Tell us about your requirement